explore -WSS

explore

author：Wikipedia 2025-09-30 23:06:50 - browse：1122

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： How to make AI work for medicine

hotspot

WSS

Diversity in medical illustrations gets boost from Chidiebere Ibe

Cancer researcher Catriona Jamieson is sending tumors into space

AstraZeneca bets AAV gene therapy will still deliver the goods

Cancer researcher Catriona Jamieson is sending tumors into space

After traumatic brain injury, life support decisions can use more time

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

entertainment

explore

explore

Bright Health sells Medicare Advantage business to Molina

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Malaria cases in Florida and Texas: Here’s what you need to know

Diversity in clinical trials starts with building trust, experts say

BioMarin wins approval for gene therapy to treat hemophilia A

Cell therapy fails to slow type 1 diabetes, but safety is established

Medical records are filled with copy

Drug firms test therapies to halt Alzheimer’s before symptoms arise

The cancer drug shortage isn’t new — and neither are the solutions

Why does health care cost so much? A reading guide

focus

Cholera vaccine supply gets boost as demand surges globally

Why rehabilitation engineers need to center patients in their research

Cancer researcher Catriona Jamieson is sending tumors into space

Cue Health's Covid

Melinda French Gates resigns from Gates Foundation

Why rehabilitation engineers need to center patients in their research

hotspot

hotspot

knowledge

Wikipedia